Jessica M. Conway
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jessica M. Conway has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Alan S. Perelson
Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM, USA
4 shared publications- Pia Abel Zur Wiesch
Institute of Integrative Biology, ETH Zurich, Zurich, Switzerland
4 shared publications - Alan S. Perelson
Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, New Mexico, United States of America
2 shared publications - Christiaan H. van Dorp
Department of Pathology and Cell Biology, Columbia University Irving Medical Center
2 shared publications - Dan H. Barouch
Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center
2 shared publications - James B. Whitney
Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
2 shared publications
Latest Publications
- Open Access
- 21 March 2026
- Published by Taylor & Francis in Journal of Biological Dynamics
- Vol. 20 (1) , 2641302
A general analytic approach to predicting the best antibiotic dosing regimen
Determining optimal antibiotic dosing strategies is complex. Clinically, some antibiotics work best in continuous low doses, while others require high repeated pulses. However, a rational understanding of the best approach depending on the specific pairing of antibiotics and bacterial species remains unclear. Using mathematical models, we analyze bacterial populations under two strategies-constant concentration and repeated dosing-with fixed pharmacodynamic and pharmacokinetic properties. Our results reveal that the shape of the dose‒response curve, which measures the bacterial net growth rate against the antibiotic concentration, is crucial. Specifically, its concavity determines the best strategy. In cases where the curve exhibits multiple concavities, additional factors, such as the tolerable dosing range, influence the regimen. These findings challenge the universal application of 'hit hard and hit early', as some recommended schedules include lower, constant doses. This work contributes to the literature on rational antibiotic prescription, aiming to minimize antibiotic use and combat antimicrobial resistance.
- 21 March 2026
- Published by Taylor & Francis in Journal of Biological Dynamics
- Vol. 20 (1) , 2641302
Open AccessA general analytic approach to predicting the best antibiotic dosing regimen
Determining optimal antibiotic dosing strategies is complex. Clinically, some antibiotics work best in continuous low doses, while others require high repeated pulses. However, a rational understanding of the best approach depending on the specific pairing of antibiotics and bacterial species remains unclear. Using mathematical models, we analyze bacterial populations under two strategies-constant concentration and repeated dosing-with fixed pharmacodynamic and pharmacokinetic properties. Our results reveal that the shape of the dose‒response curve, which measures the bacterial net growth rate against the antibiotic concentration, is crucial. Specifically, its concavity determines the best strategy. In cases where the curve exhibits multiple concavities, additional factors, such as the tolerable dosing range, influence the regimen. These findings challenge the universal application of 'hit hard and hit early', as some recommended schedules include lower, constant doses. This work contributes to the literature on rational antibiotic prescription, aiming to minimize antibiotic use and combat antimicrobial resistance.
- Open Access
A General Analytic Approach to Predicting the Best Antibiotic Dosing Regimen
Determining optimal antibiotic dosing strategies is complex. Clinically, some antibiotics work best in continuous low doses, while others require high repeated pulses. However, a rational understanding of the best approach depending on the specific pairing of antibiotic and bacterial species remains unclear. Using mathematical models, we analyze bacterial populations under two strategies – constant concentration and repeated dosing – given fixed pharmacodynamic and pharmacokinetic properties. Our results reveal that the shape of the dose-response curve, which measures bacterial net growth rate against antibiotic concentration, is crucial. Specifically, its concavity determines the best strategy. In cases where the curve exhibits multiple concavities, additional factors such as tolerable dosing range influence the regimen. These findings challenge the universal application of “hit hard and hit early,” as some recommended schedules include lower, constant doses. This work contributes to the literature on rational antibiotic prescription, aiming to minimize antibiotic use and combat antimicrobial resistance.
Open AccessA General Analytic Approach to Predicting the Best Antibiotic Dosing Regimen
Determining optimal antibiotic dosing strategies is complex. Clinically, some antibiotics work best in continuous low doses, while others require high repeated pulses. However, a rational understanding of the best approach depending on the specific pairing of antibiotic and bacterial species remains unclear. Using mathematical models, we analyze bacterial populations under two strategies – constant concentration and repeated dosing – given fixed pharmacodynamic and pharmacokinetic properties. Our results reveal that the shape of the dose-response curve, which measures bacterial net growth rate against antibiotic concentration, is crucial. Specifically, its concavity determines the best strategy. In cases where the curve exhibits multiple concavities, additional factors such as tolerable dosing range influence the regimen. These findings challenge the universal application of “hit hard and hit early,” as some recommended schedules include lower, constant doses. This work contributes to the literature on rational antibiotic prescription, aiming to minimize antibiotic use and combat antimicrobial resistance.
- Open Access
- 30 April 2024
- Published by MDPI AG in Microorganisms
- Vol. 12 (5) , 900
Incorporating Intracellular Processes in Virus Dynamics Models
In-host models have been essential for understanding the dynamics of virus infection inside an infected individual. When used together with biological data, they provide insight into viral life cycle, intracellular and cellular virus–host interactions, and the role, efficacy, and mode of action of therapeutics. In this review, we present the standard model of virus dynamics and highlight situations where added model complexity accounting for intracellular processes is needed. We present several examples from acute and chronic viral infections where such inclusion in explicit and implicit manner has led to improvement in parameter estimates, unification of conclusions, guidance for targeted therapeutics, and crossover among model systems. We also discuss trade-offs between model realism and predictive power and highlight the need of increased data collection at finer scale of resolution to better validate complex models.
- 30 April 2024
- Published by MDPI AG in Microorganisms
- Vol. 12 (5) , 900
Open AccessIncorporating Intracellular Processes in Virus Dynamics Models
In-host models have been essential for understanding the dynamics of virus infection inside an infected individual. When used together with biological data, they provide insight into viral life cycle, intracellular and cellular virus–host interactions, and the role, efficacy, and mode of action of therapeutics. In this review, we present the standard model of virus dynamics and highlight situations where added model complexity accounting for intracellular processes is needed. We present several examples from acute and chronic viral infections where such inclusion in explicit and implicit manner has led to improvement in parameter estimates, unification of conclusions, guidance for targeted therapeutics, and crossover among model systems. We also discuss trade-offs between model realism and predictive power and highlight the need of increased data collection at finer scale of resolution to better validate complex models.
- Open Access
- 31 July 2021
- Published by MDPI AG in Pharmaceutics
- Vol. 13 (8) , 1181
Mathematical Modeling of Remdesivir to Treat COVID-19: Can Dosing Be Optimized?
The antiviral remdesivir has been approved by regulatory bodies such as the European Medicines Agency (EMA) and the US Food and Drug administration (FDA) for the treatment of COVID-19. However, its efficacy is debated and toxicity concerns might limit the therapeutic range of this drug. Computational models that aid in balancing efficacy and toxicity would be of great help. Parametrizing models is difficult because the prodrug remdesivir is metabolized to its active form (RDV-TP) upon cell entry, which complicates dose–activity relationships. Here, we employ a computational model that allows drug efficacy predictions based on the binding affinity of RDV-TP for its target polymerase in SARS-CoV-2. We identify an optimal infusion rate to maximize remdesivir efficacy. We also assess drug efficacy in suppressing both wild-type and resistant strains, and thereby describe a drug regimen that may select for resistance. Our results differ from predictions using prodrug dose–response curves (pseudo-ECs). We expect that reaching 90% inhibition (EC) is insufficient to suppress SARS-CoV-2 in the lungs. While standard dosing mildly inhibits viral polymerase and therefore likely reduces morbidity, we also expect selection for resistant mutants for most realistic parameter ranges. To increase efficacy and safeguard against resistance, we recommend more clinical trials with dosing regimens that substantially increase the levels of RDV-TP and/or pair remdesivir with companion antivirals.- 31 July 2021
- Published by MDPI AG in Pharmaceutics
- Vol. 13 (8) , 1181
Open AccessMathematical Modeling of Remdesivir to Treat COVID-19: Can Dosing Be Optimized?
The antiviral remdesivir has been approved by regulatory bodies such as the European Medicines Agency (EMA) and the US Food and Drug administration (FDA) for the treatment of COVID-19. However, its efficacy is debated and toxicity concerns might limit the therapeutic range of this drug. Computational models that aid in balancing efficacy and toxicity would be of great help. Parametrizing models is difficult because the prodrug remdesivir is metabolized to its active form (RDV-TP) upon cell entry, which complicates dose–activity relationships. Here, we employ a computational model that allows drug efficacy predictions based on the binding affinity of RDV-TP for its target polymerase in SARS-CoV-2. We identify an optimal infusion rate to maximize remdesivir efficacy. We also assess drug efficacy in suppressing both wild-type and resistant strains, and thereby describe a drug regimen that may select for resistance. Our results differ from predictions using prodrug dose–response curves (pseudo-ECs). We expect that reaching 90% inhibition (EC) is insufficient to suppress SARS-CoV-2 in the lungs. While standard dosing mildly inhibits viral polymerase and therefore likely reduces morbidity, we also expect selection for resistant mutants for most realistic parameter ranges. To increase efficacy and safeguard against resistance, we recommend more clinical trials with dosing regimens that substantially increase the levels of RDV-TP and/or pair remdesivir with companion antivirals. - Open Access
Remdesivir to treat COVID-19: can dosing be optimized?
The antiviral remdesivir has been approved by regulatory bodies such as EMA and FDA for the treatment of COVID-19. However, its efficacy is debated and toxicity concerns might limit the therapeutic range of this drug. Computational models that aid in balancing efficacy and toxicity would be of great help. Parametrizing models is difficult because the prodrug remdesivir is metabolized to its active form (RDV-TP) upon cell entry, which complicates dose-activity relationships. Here, we employ a computational model that allows predicting drug efficacy based on the binding affinity of RDV-TP for its target polymerase in SARS-CoV-2. We identify an optimal infusion rate to maximize remdesivir efficacy. We also assess drug efficacy in suppressing both wild-type and resistant strains, and thereby selection of resistance. Our results differ from predictions using prodrug dose-response curves (pseudo-EC 50 s). We expect that reaching 90% inhibition (EC 90 ) is insufficient to suppress SARS-CoV-2 in lungs. While standard dosing mildly inhibits viral polymerase and therefore likely reduces morbidity, we also expect selection for resistant mutants for most realistic parameter ranges. To increase efficacy and safeguard against resistance, we recommend continuing remdesivir use with companion antivirals and/or with dosing regimens that substantially increase the levels of RDV-TP.
Open AccessRemdesivir to treat COVID-19: can dosing be optimized?
The antiviral remdesivir has been approved by regulatory bodies such as EMA and FDA for the treatment of COVID-19. However, its efficacy is debated and toxicity concerns might limit the therapeutic range of this drug. Computational models that aid in balancing efficacy and toxicity would be of great help. Parametrizing models is difficult because the prodrug remdesivir is metabolized to its active form (RDV-TP) upon cell entry, which complicates dose-activity relationships. Here, we employ a computational model that allows predicting drug efficacy based on the binding affinity of RDV-TP for its target polymerase in SARS-CoV-2. We identify an optimal infusion rate to maximize remdesivir efficacy. We also assess drug efficacy in suppressing both wild-type and resistant strains, and thereby selection of resistance. Our results differ from predictions using prodrug dose-response curves (pseudo-EC 50 s). We expect that reaching 90% inhibition (EC 90 ) is insufficient to suppress SARS-CoV-2 in lungs. While standard dosing mildly inhibits viral polymerase and therefore likely reduces morbidity, we also expect selection for resistant mutants for most realistic parameter ranges. To increase efficacy and safeguard against resistance, we recommend continuing remdesivir use with companion antivirals and/or with dosing regimens that substantially increase the levels of RDV-TP.
- Open Access
- 14 April 2021
- Published by The Royal Society in Journal of The Royal Society Interface
- Vol. 18 (177) , 20201015
Unified model of short- and long-term HIV viral rebound for clinical trial planning
Antiretroviral therapy (ART) effectively controls HIV infection, suppressing HIV viral loads. Typically suspension of therapy is rapidly followed by rebound of viral loads to high, pre-therapy levels. Indeed, a recent study showed that approximately 90% of treatment interruption study participants show viral rebound within at most a few months of therapy suspension, but the remaining 10%, showed viral rebound some months, or years, after ART suspension. Some may even never rebound. We investigate and compare branching process models aimed at gaining insight into these viral dynamics. Specifically, we provide a theory that explains both short- and long-term viral rebounds, and post-treatment control, via a multitype branching process with time-inhomogeneous rates, validated with data from Li et al. (Li et al. 2016 AIDS 30 , 343–353. ( doi:10.1097/QAD.0000000000000953 )). We discuss the associated biological interpretation and implications of our best-fit model. To test the effectiveness of an experimental intervention in delaying or preventing rebound, the standard practice is to suspend therapy and monitor the study participants for rebound. We close with a discussion of an important application of our modelling in the design of such clinical trials.
- 14 April 2021
- Published by The Royal Society in Journal of The Royal Society Interface
- Vol. 18 (177) , 20201015
Open AccessUnified model of short- and long-term HIV viral rebound for clinical trial planning
Antiretroviral therapy (ART) effectively controls HIV infection, suppressing HIV viral loads. Typically suspension of therapy is rapidly followed by rebound of viral loads to high, pre-therapy levels. Indeed, a recent study showed that approximately 90% of treatment interruption study participants show viral rebound within at most a few months of therapy suspension, but the remaining 10%, showed viral rebound some months, or years, after ART suspension. Some may even never rebound. We investigate and compare branching process models aimed at gaining insight into these viral dynamics. Specifically, we provide a theory that explains both short- and long-term viral rebounds, and post-treatment control, via a multitype branching process with time-inhomogeneous rates, validated with data from Li et al. (Li et al. 2016 AIDS 30 , 343–353. ( doi:10.1097/QAD.0000000000000953 )). We discuss the associated biological interpretation and implications of our best-fit model. To test the effectiveness of an experimental intervention in delaying or preventing rebound, the standard practice is to suspend therapy and monitor the study participants for rebound. We close with a discussion of an important application of our modelling in the design of such clinical trials.
- Open Access
- 1 October 2020
- Published by Public Library of Science (PLoS) in PLOS Computational Biology
- Vol. 16 (10) , e1008241
Models of SIV rebound after treatment interruption that involve multiple reactivation events
In order to assess the efficacy of novel HIV-1 treatments leading to a functional cure, the time to viral rebound is frequently used as a surrogate endpoint. The longer the time to viral rebound, the more efficacious the therapy. In support of such an approach, mathematical models serve as a connection between the size of the latent reservoir and the time to HIV-1 rebound after treatment interruption. The simplest of such models assumes that a single successful latent cell reactivation event leads to observable viremia after a period of exponential viral growth. Here we consider a generalization developed by Pinkevych et al. and Hill et al. of this simple model in which multiple reactivation events can occur, each contributing to the exponential growth of the viral load. We formalize and improve the previous derivation of the dynamics predicted by this model, and use the model to estimate relevant biological parameters from SIV rebound data. We confirm a previously described effect of very early antiretroviral therapy (ART) initiation on the rate of recrudescence and the viral load growth rate after treatment interruption. We find that every day ART initiation is delayed results in a 39% increase in the recrudescence rate (95% credible interval: [18%, 62%]), and a 11% decrease of the viral growth rate (95% credible interval: [4%, 20%]). We show that when viral rebound occurs early relative to the viral load doubling time, a model with multiple successful reactivation events fits the data better than a model with only a single successful reactivation event. HIV-1 persists during suppressive antiretroviral therapy (ART) due to a reservoir of latently infected cells. When ART is stopped, HIV generally rebounds within a few weeks. However, there is a small fraction of patients that do not rebound over a period of months or years. A variety of treatments are being tested for their ability to reduce the size of the latent reservoir, to induce effective immune responses against the virus, or to prevent or prolong the time to viral rebound after ART interruption. These novel treatments are typically first tested in SIV infected macaques, and the efficacy of the treatment assessed by interrupting ART and measuring the time to viral rebound. Here, we develop and test a mathematical and statistical model that describes the process of viral rebound. The model can be used for statistical inference of the efficacy of newly developed treatments. Importantly, the model takes into account that multiple recrudescence events can precede rebound. We test the model using data from early treated SIV infected macaques.
- 1 October 2020
- Published by Public Library of Science (PLoS) in PLOS Computational Biology
- Vol. 16 (10) , e1008241
Open AccessModels of SIV rebound after treatment interruption that involve multiple reactivation events
In order to assess the efficacy of novel HIV-1 treatments leading to a functional cure, the time to viral rebound is frequently used as a surrogate endpoint. The longer the time to viral rebound, the more efficacious the therapy. In support of such an approach, mathematical models serve as a connection between the size of the latent reservoir and the time to HIV-1 rebound after treatment interruption. The simplest of such models assumes that a single successful latent cell reactivation event leads to observable viremia after a period of exponential viral growth. Here we consider a generalization developed by Pinkevych et al. and Hill et al. of this simple model in which multiple reactivation events can occur, each contributing to the exponential growth of the viral load. We formalize and improve the previous derivation of the dynamics predicted by this model, and use the model to estimate relevant biological parameters from SIV rebound data. We confirm a previously described effect of very early antiretroviral therapy (ART) initiation on the rate of recrudescence and the viral load growth rate after treatment interruption. We find that every day ART initiation is delayed results in a 39% increase in the recrudescence rate (95% credible interval: [18%, 62%]), and a 11% decrease of the viral growth rate (95% credible interval: [4%, 20%]). We show that when viral rebound occurs early relative to the viral load doubling time, a model with multiple successful reactivation events fits the data better than a model with only a single successful reactivation event. HIV-1 persists during suppressive antiretroviral therapy (ART) due to a reservoir of latently infected cells. When ART is stopped, HIV generally rebounds within a few weeks. However, there is a small fraction of patients that do not rebound over a period of months or years. A variety of treatments are being tested for their ability to reduce the size of the latent reservoir, to induce effective immune responses against the virus, or to prevent or prolong the time to viral rebound after ART interruption. These novel treatments are typically first tested in SIV infected macaques, and the efficacy of the treatment assessed by interrupting ART and measuring the time to viral rebound. Here, we develop and test a mathematical and statistical model that describes the process of viral rebound. The model can be used for statistical inference of the efficacy of newly developed treatments. Importantly, the model takes into account that multiple recrudescence events can precede rebound. We test the model using data from early treated SIV infected macaques.
- Open Access
Analyzing How Changes in the Health Status of Healthcare Workers Affects Epidemic Outcomes
During a disease outbreak, healthcare workers (HCWs) are essential to treat infected individuals. However, these HCWs are themselves susceptible to contracting the disease. As more HCWs get infected, fewer are available to provide care for others, and the overall quality of care available to infected individuals declines. This depletion of HCWs may contribute to the epidemic’s severity. To examine this issue, we explicitly model declining quality of care in four differential equation-based SIR-type models with vaccination. We assume that vaccination, recovery, and survival rates are affected by quality of care delivered. We show that explicitly modelling healthcare workers and accounting for declining quality of care significantly alters model-predicted disease outcomes, specifically case counts and mortality. Models neglecting the decline of quality of care resulting from infection of HCWs may significantly under-estimate cases and mortality. These models may be useful to inform health policy that may differ for healthcare workers and the general population. Models accounting for declining quality of care may therefore improve the management interventions considered to mitigate the effects of a future outbreak.
Open AccessAnalyzing How Changes in the Health Status of Healthcare Workers Affects Epidemic Outcomes
During a disease outbreak, healthcare workers (HCWs) are essential to treat infected individuals. However, these HCWs are themselves susceptible to contracting the disease. As more HCWs get infected, fewer are available to provide care for others, and the overall quality of care available to infected individuals declines. This depletion of HCWs may contribute to the epidemic’s severity. To examine this issue, we explicitly model declining quality of care in four differential equation-based SIR-type models with vaccination. We assume that vaccination, recovery, and survival rates are affected by quality of care delivered. We show that explicitly modelling healthcare workers and accounting for declining quality of care significantly alters model-predicted disease outcomes, specifically case counts and mortality. Models neglecting the decline of quality of care resulting from infection of HCWs may significantly under-estimate cases and mortality. These models may be useful to inform health policy that may differ for healthcare workers and the general population. Models accounting for declining quality of care may therefore improve the management interventions considered to mitigate the effects of a future outbreak.
- Open Access
Models of SIV rebound after treatment interruption that involve multiple reactivation events
In order to assess the efficacy of novel HIV-1 treatments leading to a functional cure, the time to viral rebound is frequently used as a surrogate endpoint. The longer the time to viral rebound, the more efficacious the therapy. In support of such an approach, mathematical models serve as a connection between the size of the latent reservoir and the time to HIV-1 rebound after treatment interruption. The simplest of such models assumes that a single successful latent cell reactivation event leads to observable viremia after a period of exponential viral growth. Here we consider a generalization developed by Pinkevych et al. and Hill et al. of this simple model in which multiple reactivation events can occur, each contributing to the exponential growth of the viral load. We formalize and improve the previous derivation of the dynamics predicted by this model, and use the model to estimate relevant biological parameters from SIV rebound data. We confirm a previously described effect of very early antiretroviral therapy (ART) initiation on the rate of recrudescence and the viral load growth rate after treatment interruption. We find that every day ART initiation is delayed results in a 39% increase in the recrudescence rate, and a 11% decrease of the viral growth rate. We show that when viral rebound occurs early relative to the viral load doubling time, a model with multiple successful reactivation events fits the data better than a model with only a single successful reactivation event. Author Summary: HIV-1 persists during suppressive antiretroviral therapy (ART) due to a reservoir of latently infected cells. When ART is stopped, HIV generally rebounds within a few weeks. However, there is a small fraction of patients that do not rebound over a period of months or years. A variety of treatments are being tested for their ability to reduce the size of the latent reservoir, to induce effective immune responses against the virus, or to prevent or prolong the time to viral rebound after ART interruption. These novel treatments are typically first tested in SIV infected macaques, and the efficacy of the treatment assessed by interrupting ART and measuring the time to viral rebound. Here, we develop and test a mathematical and statistical model that describes the process of viral rebound. The model can be used for statistical inference of the efficacy of newly developed treatments. Importantly, the model takes into account that multiple recrudescence events can precede rebound. We test the model using data from early treated SIV infected macaques.
Open AccessModels of SIV rebound after treatment interruption that involve multiple reactivation events
In order to assess the efficacy of novel HIV-1 treatments leading to a functional cure, the time to viral rebound is frequently used as a surrogate endpoint. The longer the time to viral rebound, the more efficacious the therapy. In support of such an approach, mathematical models serve as a connection between the size of the latent reservoir and the time to HIV-1 rebound after treatment interruption. The simplest of such models assumes that a single successful latent cell reactivation event leads to observable viremia after a period of exponential viral growth. Here we consider a generalization developed by Pinkevych et al. and Hill et al. of this simple model in which multiple reactivation events can occur, each contributing to the exponential growth of the viral load. We formalize and improve the previous derivation of the dynamics predicted by this model, and use the model to estimate relevant biological parameters from SIV rebound data. We confirm a previously described effect of very early antiretroviral therapy (ART) initiation on the rate of recrudescence and the viral load growth rate after treatment interruption. We find that every day ART initiation is delayed results in a 39% increase in the recrudescence rate, and a 11% decrease of the viral growth rate. We show that when viral rebound occurs early relative to the viral load doubling time, a model with multiple successful reactivation events fits the data better than a model with only a single successful reactivation event. Author Summary: HIV-1 persists during suppressive antiretroviral therapy (ART) due to a reservoir of latently infected cells. When ART is stopped, HIV generally rebounds within a few weeks. However, there is a small fraction of patients that do not rebound over a period of months or years. A variety of treatments are being tested for their ability to reduce the size of the latent reservoir, to induce effective immune responses against the virus, or to prevent or prolong the time to viral rebound after ART interruption. These novel treatments are typically first tested in SIV infected macaques, and the efficacy of the treatment assessed by interrupting ART and measuring the time to viral rebound. Here, we develop and test a mathematical and statistical model that describes the process of viral rebound. The model can be used for statistical inference of the efficacy of newly developed treatments. Importantly, the model takes into account that multiple recrudescence events can precede rebound. We test the model using data from early treated SIV infected macaques.